John Malona

John Malona has a long and varied work experience. John began their career in 2001 as an Undergraduate Research at Colgate University, where they synthesized dithiocarbamates linked to trialkyl stannanes via carbon spacers for use as potential anti-fungal/anti-fouling agents, determined thermodynamic parameters of conformational exchange for cis- and trans-1,4-bromochlorocyclohexane by VT-NMR, and worked under the advisement of John C. In 2003, they moved to University of Rochester as a Doctoral Research, where they completed the total synthesis of (±) -rocaglamide and developed the first catalytic Nazarov reaction methodology for heteroaromatic substrates. In 2008, they became a Post-doctoral Research at Princeton University, where they explored approaches to metabolically stable silicon containing analogues of cyclopamine, a ligand for the trans-membrane protein, smoothened, developed a directed ortho-metalation strategy for the synthesis of silicon heterocycles, and utilized intramolecular dipolar cycloaddition reactions to synthesize a range of benzannulated silacycles. In 2011, they joined Avila Tx as a Scientist. In 2012, they moved to Celgene as a Senior Scientist, and in 2018 they joined Jnana Therapeutics as the Director of Chemistry and Associate Director.

John Malona completed their education with a Post-Doctoral from Princeton University in 2010, a Ph.D from the University of Rochester in 2008, and a B.A. from Colgate University in 2003, all in the field of Organic Synthesis. John also earned a B.A. in Chemistry and Philosophy from Colgate University in 1999.